Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial

To report patient-reported outcomes (PROs) of a phase III trial evaluating total androgen suppression (TAS) combined with dose-escalated radiation therapy (RT) for patients with intermediate-risk prostate cancer. Patients with intermediate-risk prostate cancer were randomly assigned to dose-escalate...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of clinical oncology 2023-06, Vol.41 (17), p.3217-3224
Hauptverfasser:	Movsas, Benjamin, Rodgers, Joseph P, Elshaikh, Mohamed A, Martinez, Alvaro A, Morton, Gerard C, Krauss, Daniel J, Yan, Di, Citrin, Deborah E, Hershatter, Bruce W, Michalski, Jeff M, Ellis, Rodney J, Kavadi, Vivek S, Gore, Elizabeth M, Gustafson, Gary S, Schulz, Craig A, Velker, Vikram M, Olson, Adam C, Cury, Fabio L, Papagikos, Michael A, Karrison, Theodore G, Sandler, Howard M, Bruner, Deborah W
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - therapeutic use Androgens - therapeutic use Humans Male ORIGINAL REPORTS Patient Reported Outcome Measures Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Quality of Life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!